B-25 | Two-Year Outcomes in Patients with Bifurcation Lesions treated with Resolute ONYX ZES: Final Results from the RESOLUTE ONYX Bifurcation Study

Matthew J. Price; Loukas Boutis; Ajay J. Kirtane; Stanley Chetcuti; Petra Poliačiková; Joseph Dens; Michael Attubato; Yale L. Wang; Aiguo Patrick Hu; Douglas Spriggs; Joshua Krasnow; Yiannis S. Chatzizisis; Adel Aminian; Ronald Caputo; Alpesh Shah; Michelle Dauler; Sherif Ibrahim; Te‐Hsin Lung; Roxana Mehran

doi:10.1016/j.jscai.2022.100132

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Bifurcations are a challenging lesion subset for percutaneous coronary intervention. In the RESOLUTE ONYX Bifurcation study, we evaluated the 2-year clinical outcomes of patients with bifurcation lesions treated with the Resolute Onyx zotarolimus-eluting stent (ZES).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Price et al. (2022) studied this question.

synapsesocial.com/papers/6a901ccfa5ba1763c9040f5b https://doi.org/10.1016/j.jscai.2022.100132

View Full Paper

Ask AI

Bookmark

Share

B-25 | Two-Year Outcomes in Patients with Bifurcation Lesions treated with Resolute ONYX ZES: Final Results from the RESOLUTE ONYX Bifurcation Study

Ask about this paper

Abstract

Discussion

Cite This Study

B-25 | Two-Year Outcomes in Patients with Bifurcation Lesions treated with Resolute ONYX ZES: Final Results from the RESOLUTE ONYX Bifurcation Study

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading